ralwel / iStockphoto.com
French cell therapy company Cellectis has announced plans to make two CRISPR patents, which were recently granted by the US Patent and Trademark Office, available for licensing.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Patent and Trademark Office, Cellectis, editing T-cells, oncology research, CRISPR technology, CRISPR patent, gene editing, licensing CRISPR
